Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Ingrid Mayer

10 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBRE1681

    01/27/2017

    A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

    Treatment

    VICCBRE15147

    01/20/2017

    A Randomized Phase II Trial of Fulvestrant with or without Ribociclib (LEE011) After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Advanced Hormone Receptor Positive, HER2 Negative Breast Cancer

    Treatment

    VICCBRE1640

    11/10/2016

    PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Treatment

    VICCBRE15120

    08/18/2016

    Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor-Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamic Markers (TBCRC035)

    Treatment

    VICCBRE1562

    03/15/2016

    SOLAR-1: A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer which Progressed on or After Aromatase Inhibitor Treatment

    Treatment

    VICCBRE1546

    12/01/2015

    The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

    Treatment

    ECOGBREEA1131

    09/24/2015

    A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    VICCBRE1391

    04/24/2014

    A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

    Treatment

    VICCPHI1248

    10/12/2012

    An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer


    Print this page for your doctor